Obesity News

In adults with obesity and obstructive sleep apnea, bariatric surgery was associated with reduced risk for major adverse CV events compared with no surgery, researchers reported.

SAN DIEGO — Adults with obesity and type 2 diabetes who undergo bariatric or metabolic surgery have a lower HbA1c and greater weight loss than those who did not undergo surgery at 7 and 12 years of follow-up, according to trial data.

SAN DIEGO — Matthias Tschöp, MD, has played a major role in the recent influx of novel therapies for the treatment of diabetes and obesity.

SAN DIEGO — Adults with obesity who received the highest dose of a once-weekly injection of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo, data from a phase 2 study show.

SAN DIEGO — Oral semaglutide 50 mg induces more than 15% weight loss in adults with obesity at 68 weeks and can reduce HbA1c by 2 percentage points at 52 weeks for those with type 2 diabetes, according to data from two phase 3 trials.

SAN DIEGO — In this video exclusive, Sangeeta Kashyap, MD, discusses how weight loss is the key to type 2 diabetes remission and how remission can be possible in both short- and long-term scenarios.

SAN DIEGO — Combination cagrilintide and semaglutide therapy is associated with a 15.6% weight loss and 2.2% reduction in HbA1c among adults with obesity and type 2 diabetes, according to a speaker.

SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.

SAN DIEGO — Diabetes and nonalcoholic fatty liver disease are “common bedfellows” due to processes brought on by insulin resistance, but a reduction in dietary sugars combined with exercise can reverse the damage, according to a speaker.

SAN DIEGO — Adults with obesity and without diabetes receiving the oral GLP-1 receptor agonist orforglipron lost 8.6% to 12.6% of their body weight at 26 weeks, according to a data from a phase 2 trial.